Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Anti-HER2 CAR-T cells

PreclinicalCell therapy

UUTC Therapeutics Inc.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

HER2-Positive Advanced Malignant Solid TumorsRecruiting

HER2-Positive Advanced Malignant Solid TumorsPreclinical

Recruiting

Timeline

Expected Milestones

Q2 2028

HER2-Positive Advanced Malignant Solid Tumors

NCT06658951

Clinical

Trials by Indication[1]

HER2-positive Advanced Malignant Solid Tumors1 trial

Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors

Recruiting·UUTC Therapeutics Inc.·N/A·NCT06658951·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Anti-HER2 CAR-T cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anti-HER2 CAR-T cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anti-HER2 CAR-T cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — UTC Therapeutics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Preclinical[1]
Company: UUTC Therapeutics Inc.

Related News